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Abstract
Maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 (four-event stack maize) was produced by
conventional crossing to combine four single events: MON 89034, 1507, NK603 and DAS-40278-9. The
GMO Panel previously assessed the four single events and four of their subcombinations and did not
identify safety concerns. No new data on the maize single events or their four subcombinations that
could lead to modiﬁcation of the original conclusions on their safety have been identiﬁed. The
molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicates
that the combination of the single maize events and of the newly expressed proteins in the four-event
stack maize does not give rise to food/feed safety and nutritional concerns. The GMO Panel concludes
that the four-event stack maize, as described in this application, is as safe as and nutritionally
equivalent to its non-GM comparator and the non-GM reference varieties tested. In the case of
accidental release of viable grains of the four-event stack maize into the environment, this would not
raise environmental safety concerns. The GMO Panel assessed the likelihood of interactions among the
single events in the six maize subcombinations for which no experimental data were provided, and
concludes that these are expected to be as safe as and nutritionally equivalent to the single events, the
previously assessed subcombinations and the four-event stack maize. The post-market environmental
monitoring plan and reporting intervals are in line with the intended uses of the four-event stack maize.
No post-market monitoring for food/feed is necessary. The GMO Panel concludes that the four-event
stack maize and its subcombinations are as safe as its non-GM comparator and the tested non-GM
reference varieties with respect to potential effects on human and animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2013-112 under Regulation (EC) No 1829/2003
from Dow AgroSciences, the Panel on Genetically Modiﬁed Organisms of the European Food Safety
Authority (hereafter referred to as the ‘GMO Panel’) was asked to deliver a scientiﬁc opinion on genetically
modiﬁed (GM) maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 and its subcombinations
independently of their origin (referred to hereafter as the ‘subcombinations’). The scope of application
EFSA-GMO-NL-2013-112 is for the placing on the market of maize MON 89034 9 1507 9 NK603 9 DAS-
40278-9 and all its subcombinations independently of their origin for food and feed uses, import and
processing.
The term ‘subcombination’ refers to any combination of up to three of the events present in the
four-event stack maize. The safety of subcombinations occurring as segregating progeny in the
harvested grains of maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 is evaluated in the context of
the assessment of the four-event stack maize in Section 3.3 of the present GMO Panel scientiﬁc
opinion. The safety of subcombinations that have either been, or could be produced by conventional
crossing through targeted breeding approaches, and which can be bred, produced and marketed
independently of the four-event stack, are risk assessed in Section 3.4 of the present scientiﬁc opinion.
In delivering its scientiﬁc opinion, the GMO Panel considered the data available on the single
events, the four-event stack maize, three two-event stack and one three-event stack subcombinations,
the scientiﬁc comments submitted by the Member States and the relevant scientiﬁc literature. The
four-event stack maize was produced by conventional crossing to combine four single maize events:
MON 89034 expressing the Cry1A.105 and Cry2Ab2 proteins which confer resistance to speciﬁc
lepidopteran pests; 1507 expressing the Cry1F protein which confers protection against speciﬁc
lepidopteran pests and phosphinothricin acetyltransferase protein for tolerance to glufosinate-
containing herbicides; NK603 expressing the CP4 EPSPS protein for tolerance to glyphosate-containing
herbicides; and DAS-40278-9 expressing the aryloxyalkanoate dioxygenase-1 protein for tolerance to
2,4-dichlorophenoxyacetic acid- and aryloxyphenoxypropionate-containing herbicides.
The GMO Panel evaluated the four-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring (PMEM) of GM plants.
For application EFSA-GMO-NL-2013-112, previous assessments of the four single maize events
MON 89034, 1507, NK603 and DAS-40278-9, the three-event stack maize MON 89034 9 1507 9
NK603 and the two-event stack maize MON 89034 9 NK603, MON 89034 9 1507 and 1507 9 NK603
provided a basis to evaluate the four-event stack maize and all its subcombinations. No concerns on
their safety were identiﬁed by the GMO Panel in the previous assessments. No safety issue concerning
the four single maize events was identiﬁed by the updated bioinformatic analyses, nor reported by the
applicant since the publication of the previous GMO Panel scientiﬁc opinions. Therefore, the GMO
Panel considers that its previous conclusions on the safety of the single maize events remain valid.
For the four-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterisation data establish that the events stacked in maize MON 89034 9
1507 9 NK603 9 DAS-40278-9 have retained their integrity. Protein expression analyses show that the
levels of the newly expressed proteins in the four-event stack maize are similar to those of either the
single event DAS-40278-9 or the already assessed three-event stack maize MON 89034 9
1507 9 NK603. No indications of interactions that may affect the integrity of the events and the levels
of the newly expressed proteins in this four-event stack maize are identiﬁed.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identiﬁed no differences between maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 and the non-
GM comparator that required further assessment for food and feed safety or environmental impact,
except for levels of cystine, isoleucine, phenylalanine, rafﬁnose, manganese and b-carotene in grain
and levels of total fat in forage, and plant height, insect damage and pollen shape which were further
assessed and not found to have a safety impact.
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The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicates
that the combination of the single maize events and of the newly expressed proteins in the four-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the maize MON 89034 9 1507 9 NK603 9 DAS-40278-9, as described in this
application, is as safe as and nutritionally equivalent to its non-GM comparator and the non-GM
reference varieties tested.
Considering the combined events and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that maize
MON 89034 9 1507 9 NK603 9 DAS-40278-9 would not raise safety concerns in the case of
accidental release of viable GM maize grains into the environment.
Since no new safety concerns were identiﬁed for the previously assessed two-event stack maize
MON 89034 9 1507, MON 89034 9 NK603 and 1507 9 NK603 as well as the three-event stack maize
MON 89034 9 1507 9 NK603, and no new data leading to the modiﬁcation of the original conclusions
on safety were identiﬁed, the GMO Panel considers that its previous conclusions on these maize
subcombinations remain valid. For the remaining six subcombinations included in the scope of EFSA-
GMO-NL-2013-112 for which no experimental data have been provided, the GMO Panel assessed the
possibility of interactions between the events, and concluded that different combinations of the events
MON 89034, 1507, NK603 and DAS-40278-9 would not raise safety concerns. These subcombinations
are therefore expected to be as safe as and nutritionally equivalent to the single events, the previously
assessed subcombinations and the four-stack maize MON 89034 9 1507 9 NK603 9 DAS-40278-9.
Given the absence of safety concerns for foods and feeds from maize MON 89034 9
1507 9 NK603 9 DAS-40278-9 and all its subcombinations, the GMO Panel considers that post-market
monitoring of these products is not necessary. The PMEM plan and reporting intervals are in line with
the intended uses of the four-event stack maize and its subcombinations.
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1. Introduction
The scope of application EFSA-GMO-NL-2013-112 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modiﬁed (GM) herbicide-tolerant insect-resistant maize
MON 89034 9 1507 9 NK603 9 DAS-40278-9 and all its subcombinations independently of their
origin.
1.1. Background
On 11 January 2013, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2013-112 for authorisation of maize
MON 89034 9 1507 9 NK603 9 DAS-40278-9 (hereafter referred to as ‘the four-event stack maize’)
(Unique Identiﬁer MON-89Ø34-3 9 DAS-Ø15Ø7-1 9 MON-ØØ6Ø3-6 9 DAS-4Ø278-9), submitted by
Dow AgroSciences (hereafter referred to as ‘the applicant’) according to Regulation (EC) No 1829/2003.1
Following receipt of application EFSA-GMO-NL-2013-112, EFSA informed EU Member States and the
European Commission, and made the application available to them. Simultaneously, EFSA published
the summary of the application.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and, when needed, asked the applicant to supplement the initial application. On
29 August 2014, EFSA declared the application valid.
From the validity date, EFSA and its scientiﬁc Panel on Genetically Modiﬁed Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientiﬁc
opinion on application EFSA-GMO-NL-2013-112. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU Member States and European Commission (for further details, see the
Section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU Member States, including national Competent Authorities within the meaning of Directive
2001/18/EC.3 The EU Member States had 3 months to make their opinion known on application EFSA-
GMO-NL-2013-112 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientiﬁc risk assessment of the four-event stack maize and all its
subcombinations independently of their origin, for food and feed uses, import and processing.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
In addition to the present scientiﬁc opinion, EFSA was also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003, but not to give an opinion on them,
because they pertain to risk management.4
2. Data and methodologies
2.1. Data
The GMO Panel based its scientiﬁc assessment of the four-event stack maize on the valid
application EFSA-GMO-NL-2013-112, additional information provided by the applicant during the risk
assessment, relevant scientiﬁc comments submitted by EU Member States and relevant peer-reviewed
scientiﬁc publications.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2013-00079.
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
4 These particulars can be found in the technical report by EFSA on the application EFSA-GMO-NL-2013-112, made available in
the EFSA Register of Questions.
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2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 1829/2003, its applicable guidelines (i.e. EFSA GMO Panel, 2010a,b, 2011a,b) and explanatory
notes (i.e. EFSA, 2017a,b) for the risk assessment of GM plants.
In the context of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2013-112 covers the four-event stack maize MON 89034 9 1507 9
NK603 9 DAS-40278-9 and all its subcombinations independently of their origin (Table 1).
The term ‘subcombination’ refers to any combination of up to three of the events present in the
four-event stack maize.
The safety of subcombinations occurring as segregating progeny in harvested grains of the four–
event stack maize is evaluated in the context of the assessment of the four-event stack maize in
Section 3.3 of the present GMO Panel scientiﬁc opinion.
‘Subcombination’ also covers combinations of up to three of the maize events MON 89034, 1507,
NK603 or DAS-40278-9 that have either been or could be produced by conventional crossing through
targeted breeding approaches (EFSA GMO Panel, 2011a). These are maize stacks that can be bred,
produced and marketed independently of the four-event stack maize. These subcombinations are
assessed in Section 3.4 of this scientiﬁc opinion.
The four-event stack maize was produced by conventional crossing to combine four single maize
events: MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); 1507 (expressing the Cry1F and
phosphinothricin acetyl transferase (PAT) proteins); NK603 (expressing the 5-enolpyruvylshikimate-3-
phosphate synthase (CP4 EPSPS) and its variant CP4 EPSPS L214P protein); and DAS-40278-9
(expressing the aryloxyalkanoate dioxygenase 1 (AAD-1) protein).
Herbicidal tolerance traits are achieved by the expression of AAD-1 protein from
Sphingobium herbicidovorans, CP4 EPSPS proteins from Agrobacterium sp. strain CP4, and PAT protein
from Streptomyces viridochromogenes. Insecticidal resistance traits are achieved by the expression of
Cry1A.105, Cry2Ab2 and Cry1F proteins from Bacillus thuringiensis, which confer protection against
speciﬁc lepidopteran pests.
All four single maize events and four of the subcombinations (three two-event stacks and one
three-event stack) have been previously assessed (see Table 2). No concerns for human and animal
health, or environmental safety were identiﬁed.
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2013-112
Degree of stacking Events
Four-event stack maize MON 89034 9 1507 9 NK603 9 DAS-40278-9
Three-event stack maize MON 89034 9 1507 9 NK603
MON 89034 9 NK603 9 DAS-40278-9
MON 89034 9 1507 9 DAS-40278-9
1507 9 NK603 9 DAS-40278-9
Two-event stack maize MON 89034 9 1507
MON 89034 9 NK603
MON 89034 9 DAS-40278-9
1507 9 NK603
1507 9 DAS-40278-9
NK603 9 DAS-40278-9
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3.2. Updated information on the single events5
Since the publication of the GMO Panel scientiﬁc opinions on the four single maize events (Table 2),
no safety issue concerning the four single events has been reported by the applicant.
The applicant clariﬁed that the 1507 maize sequence reported for the four-event stack maize
contained one silent nucleotide change in the insert sequence compared to the corrected original 1507
maize sequence (EFSA GMO Panel, 2018a,b, 2019). Analysis of the new sequencing data and
bioinformatic analyses performed on the new sequence does not identify any need for further safety
assessment.
Updated bioinformatic analyses on the junction regions for maize events MON 89034, 1507, NK603
and DAS-40278-9, using the methodology speciﬁed in the 2011 GMO Panel Guidance Document (EFSA
GMO Panel, 2011a) conﬁrm that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1A.105,
Cry2Ab2, Cry1F, PAT, CP4 EPSPS and AAD-1 proteins reveal no signiﬁcant similarities to toxins and
allergens. Updated bioinformatic analyses of the newly created open reading frames (ORFs) within the
insert or spanning the junctions between the insert and genomic DNA indicate that the expression of
an ORF showing signiﬁcant similarities to toxins or allergens is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination,
the applicant performed a sequence identity analysis for maize events MON 89034, 1507, NK603 and
DAS-40278-9 with microbial DNA. The likelihood and potential consequences of plant-to-bacteria gene
transfer are described in Section 3.3.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
Table 2: Single maize events and subcombinations of maize MON 89034 9 1507 9 NK603 9 DAS-
40278-9 previously assessed by the GMO Panel
Events Application or mandate Reference
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
1507 C/NL/00/10 EFSA (2004a)
C/ES/01/01 EFSA (2005a)
EFSA-GMO-NL-2004–02 EFSA (2005b)
EFSA-GMO-RX-1507 EFSA (2009a)
EFSA-M-2012-0231(a) EFSA GMO Panel (2012)
EFSA-GMO-RX-001 EFSA GMO Panel (2017a)
NK603 C/ES/00/01 EFSA (2007)
Article 4 of the Novel Food
Regulation (EC) No 258/97
EFSA (2004b)
EFSA-GMO-NL-2005-22 EFSA (2009b)
EFSA-GMO-RX-NK603 EFSA (2009b)
DAS–40278–9 EFSA-GMO-NL-2010-89 EFSA GMO Panel (2016)
MON 89034 9 1507 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
EFSA-M-2011-0066(b) EFSA GMO Panel (2011c)
EFSA-GMO-BE-2013-118 EFSA GMO Panel (2017b)
MON 89034 9 NK603 EFSA-GMO-NL-2007-38 EFSA GMO Panel (2009)
EFSA-M-2011-0066(b) EFSA GMO Panel (2011c)
EFSA-GMO-BE-2013-117 EFSA GMO Panel (2017c)
1507 9 NK603 EFSA-GMO-UK-2004-05 EFSA (2006)
EFSA-M-2011-0066(b) EFSA GMO Panel (2011c)
EFSA-GMO-NL-2011-92 EFSA GMO Panel (2017d)
EFSA-GMO-RX-008 EFSA GMO Panel (2018a)
MON 89034 9 1507 9 NK603 EFSA-GMO-NL-2009-65 EFSA GMO Panel (2010d)
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00712
(b): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00169
5 Dossier: Part II – Section 1.2.2.2; Additional information: 13/1/2017, 19/9/2017 and 30/7/2018.
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3.3. Risk assessment of the four-event stack maize
MON 89034 3 1507 3 NK603 3 DAS-40278-9
3.3.1. Molecular characterisation6
Possible interactions that would affect the integrity of the events, newly expressed proteins levels
or the biological function conferred by the individual inserts are considered below.
3.3.1.1. Genetic elements and their biological function
Maize events MON 89034, 1507, NK603 and DAS-40278-9 were combined by conventional crossing
to produce the four-event stack maize. The structure of the inserts in the four-event stack maize are
described in detail in the respective EFSA scientiﬁc opinions (Table 2) and no new genetic
modiﬁcations were involved. Genetic elements in the expression cassettes of the single events are
summarised in Table 3. Intended effects of the inserts in maize MON 89034 9 1507 9 NK603 9 DAS-
40278-9 are summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the three Cry proteins in susceptible insects.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
MON 89034 9 1507 9 NK603 9 DAS-40278-9
Event Promoter 50 UTR
Transit
peptide
Coding region* Terminator
MON 89034 35S
(CaMV)
CAB
(Triticum sp.)
– cry1A.105
(Bacillus thuringiensis)
Hsp17
(Triticum sp.)
35S
(FMV)
– CTP
(Z. mays)
cry2Ab2
(B. thuringiensis)
nos
(Agrobacterium
tumefaciens)
1507(a) ubiZM1
(Zea mays)
– – cry1F
(B. thuringiensis)
ORF25PolyA
(A. tumefaciens)
35S
(CaMV)
– – pat
(Streptomyces
viridochromogenes)
35S
(CaMV)
NK603(b) ract1
(O. sativa)
ract1
(O. sativa)
CTP2
(A. thaliana)
CP4 epsps
(Agrobacterium sp.)
nos
(A. tumefaciens)
35S
(CaMV)
I-Hsp70
(Z. mays)
CTP2
(A. thaliana)
CP4 epsps L214P
(Agrobacterium sp.)
nos
(A. tumefaciens)
DAS–40278–9 ZmUbi1
(Z. mays)
– – aad-1
(Sphingobium
herbicidovorans)
ZmPer5 30 UTR
(Z. mays)
CaMV: cauliﬂower mosaic virus; FMV: ﬁgwort mosaic virus.
*: all gene sequences are codon-optimised for expression in plants.
–: when no element was speciﬁcally introduced to optimise expression.
(a): Maize 1507 also contains partial fragments of the cry1F and pat genes at a single locus in the nuclear genome.
(b): Maize NK603 also includes at the 30 end an additional 217 bp DNA fragment of the rice actin promoter, lacking sequences
needed for promoter activity.
6 Dossier: Part II – Section A.2; Additional information: 13/1/2017, 19/9/2017, 24/11/2017, 18/1/2018, 12/3/2018 and 30/7/2018.
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3.3.1.2. Integrity of the events in the four-event stack
The genetic stability of the inserted DNA over multiple generations in the single maize events
MON 89034, 1507, NK603 and DAS-402789 was previously demonstrated (see Table 2). Integrity of
these events in the four-event stack maize was demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts
Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4-EPSPS and AAD-1 protein levels were analysed by enzyme-
linked immunosorbent assay (ELISA) in material harvested from a ﬁeld trial across 10 locations in the
Table 4: Characteristics and intended effects of the events stacked in maize MON 89034 9 1507 9
NK603 9 DAS-40278-9
Event Protein Donor organism and biological function Intended effects in the GM plant
MON 89034 Cry1A.105 Based on genes from Bacillus thuringiensis
subsp. kurstaki and subsp. aizawai.
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Event MON 89034 expresses a
modiﬁed version of the Cry1A-type
protein. Cry1A.105 is a protein toxic
to certain lepidopteran larvae
Cry2Ab2 Based on a gene from Bacillus thuringiensis
subsp. kurstaki. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry)
genes (Schnepf et al., 1998; Ellis et al.,
2002)
Event MON 89034 expresses the
Cry2Ab2, a protein toxic to certain
lepidopteran larvae
1507 Cry1F Based on a gene from Bacillus thuringiensis
subsp. aizawai. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry)
genes (Schnepf et al., 1998; Ellis et al.,
2002).
Event 1507 expresses a truncated
version of the Cry1F protein. Cry1F is
a protein toxic to certain lepidopteran
larvae
PAT Based on a gene from Streptomyces
viridochromogenes T€u494.
Phosphinothricin-acetyl-transferase (PAT)
enzyme acetylates L-glufosinate-ammonium
(Thompson et al., 1987; Wohlleben et al.,
1988; Eckes et al., 1989)
Event 1507 expresses the PAT protein
which confers tolerance to glufosinate
ammonium-based herbicides (Droge-
Laser et al., 1994).
NK603 CP4 EPSPS Based on a gene from Agrobacterium strain
CP4.
5-Enopyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event NK603 expresses the bacterial
CP4 EPSPS protein which confers
tolerance to glyphosate-containing
herbicides as it has lower afﬁnity
towards glyphosate than the plant
endogenous enzyme
CP4 EPSPS
L214P
Based on a gene from Agrobacterium strain
CP4.
5-Enopyruvyl-shikimate-3-phosphate
synthase (EPSPS) is an enzyme involved in
the shikimic acid pathway for aromatic amino
acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event NK603 expresses a modiﬁed
version of the bacterial CP4 EPSPS
protein which confers tolerance to
glyphosate-containing herbicides as it
has lower afﬁnity towards glyphosate
than the plant endogenous enzyme
DAS-40278-9 AAD-1 Based on a gene from Sphingobium
herbicidovorans. Aryloxyalkanoate
dioxygenase (AAD-1) facilitates the
breakdown of phenoxy auxin and
aryloxyphenoxypropionate herbicides into
carbon sources for the bacterium (Wright
et al., 2009)
Event DAS–40278–9 expresses AAD-1
protein which degrades the herbicide
2,4-dichlorophenoxyacetic acid (2,4-
D) and thus confers tolerance to this
herbicide
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US in 2010. Four-event stack maize samples analysed included leaf (V2–V4, V9, R1), pollen (R1), root
(R1), forage (R4), whole plant (R6) and grain (R6) treated and not treated with the intended herbicides.
The applicant indicated that a small percentage of the non-GM controls showed detectable levels of the
proteins, possibly resulting from cross-contamination or sampling error. Additional information
requested by the GMO Panel did not allow limiting this observation to particular locations. Considering
that the proportion of contaminated controls was very low, and given the high number of samples
analysed, the impact on the mean expression values presented in Appendix 1 is considered negligible.
In order to assess changes in protein expression levels which may result from potential interactions
between the events, protein levels were determined for the four-event stack maize and one
corresponding single event or the previously assessed three-event stack maize MON 89034 9
1507 9 NK603 (see Table 2) in different parts of the plant grown without intended herbicide regimes.
The levels of the proteins in the four-event stack maize were comparable in all tissues to those of
either the single event DAS-40278-9 or the previously assessed three-event stack MON 89034 9 1507
9 NK603 (EFSA GMO Panel, 2010d; Appendix 1). Therefore, there is no indication of interactions that
may affect the integrity of the events and the levels of the newly expressed proteins in this stack.
3.3.1.4. Conclusion on molecular characterisation
The molecular data establish that the events stacked in the four-event stack maize have retained
their integrity. Protein expression analyses show that the levels of the newly expressed proteins in the
four-event stack maize are similar to those of either the single event DAS-40278-9 or the already
assessed three-event stack maize MON 89034 9 1507 9 NK603. Therefore, there is no indication of
an interaction that may affect the integrity of the events and the levels of the newly expressed
proteins in this stack.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry proteins in susceptible insects, which
is dealt with in Section 3.3.4.4.
3.3.2. Comparative analysis7
3.3.2.1. Choice of comparator and production of material for the comparative analysis
Application EFSA-GMO-NL-2013-112 presents data on agronomic and phenotypic characteristics as
well as on forage and grain composition of the four-event stack maize derived from ﬁeld trials
performed at 10 sites in the US during the 2010 growing season (Table 5).
The four-event stack maize was obtained by conventional crossing: events MON 89034, 1507 and
NK603 were introgressed in the inbred maize line 7SH382, while event DAS-40278-9 was introgressed
in maize XHH13. As documented by the pedigree, the four single events, after backcrossing, were
combined in a hybrid maize with a genetic background (F1) of 7SH382 9 XHH13. The same two inbred
maize lines (7SH382 and XHH13) were crossed to produce the non-GM hybrid maize used as
comparator. On the basis of the provided pedigree, documenting the production of the four-event stack
GM maize, the GMO Panel considers that hybrid maize 7SH382 9 XHH13 is a suitable comparator.
The ﬁeld trial sites were located in major maize growing areas of the US,8 representing regions of
diverse agronomic practices and environmental conditions. At each site, the following materials were
grown in a randomised complete block design with four replicates: the four-event stack maize treated,
a non-GM comparator and three non-GM reference varieties9 all treated (sprayed) with plant protection
Table 5: Overview of comparative analysis studies with maize MON 89034 9 1507 9 NK603 9
DAS-40278-9
Study focus Study details Comparator
Non-GM commercial
reference varieties
Agronomic, phenotypic and
compositional analysis
Field study, 2010, US, 10 sites 7SH382 9 XHH13 Six
7 Dossier: Part II – Section A.3; Additional information: 6/3/2017.
8 The ﬁeld sites were located in Richland (IA), Lime Springs (IA), Atlantic (IA), Carlyle (IL), Wyoming (IL), Sheridan (IN),
Fisk (MO), Brunswick (NE), York (NE) and Germansville (PA).
9 The reference varieties used were: Dekalb 6170, Golden Harvest 8920, Middlekoop 5513, Middlekoop 6614, Middlekoop C110
and Pioneer 33W82.
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products (PPP) according to local requirements, and the four-event stack maize treated with the
intended herbicides (2,4-D-, glyphosate-, glufosinate-ammonium- and quizalofop-containing herbicides)
in addition to the other PPP.
Statistical analysis of ﬁeld trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2010 ﬁeld
trial study followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a). This
included, for each of the two treatments of the four-event stack maize, the application of a difference
test (between the GM maize and the non-GM comparator) and an equivalence test (between the GM
maize and the set of non-GM maize reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).10
3.3.2.2. Agronomic and phenotypic analysis
A total of 26 agronomic and phenotypic endpoints, including observations on the biotic and abiotic
interactions, were analysed.11
Data for 12 endpoints12 were considered not suitable for a parametric analysis; for these, a
Wilcoxon signed-rank (WSR) test was used to check for differences between the GM maize and the
non-GM comparator.
The remaining 14 endpoints were analysed as described in Section 3.3.2.1, with the following
outcomes:
• For the four-event stack maize not treated with the intended herbicides, statistically signiﬁcant
differences were identiﬁed for time to silking, time to pollen shed, ear height, stay green, plant
height and insect damage. All endpoints fell under equivalence category I or II, except for
plant height (equivalence category III) and insect damage for which the test of equivalence
was not applied because the variability among the non-GM reference varieties was estimated
to be zero.13
• For the four-event stack maize treated with the intended herbicides, statistically signiﬁcant
differences were identiﬁed for time to silking, time to pollen shed, ear height, disease
incidence, insect damage, stay green, ﬁnal population, plant height and pollen shape at
30 min. All endpoints fell under category I or II except for insect damage and pollen shape at
30 min, for which the test of equivalence was not applied because the variability among the
non-GM reference varieties was estimated to be zero.14
Of the endpoints analysed with the WSR test, statistically signiﬁcant differences were identiﬁed for
days to maturity (for both GM maize treatments) and pollen shape at 120 min (for GM maize treated
with the intended herbicides). However, in both cases, the average values for the GM maize were
within the range of the non-GM reference varieties.
3.3.2.3. Compositional analysis
Forage and grain harvested from the ﬁeld trial study in the US in 2010 (Table 5) were analysed for
82 constituents (9 in forage and 73 in grain), including the key constituents recommended by the
OECD (OECD, 2002). For 17 grain constituents,15 more than 50% of the observations were below the
10 The results of the equivalence test are categorised into four possible outcomes: category I (indicating full equivalence to the
non-GM reference varieties); category II (equivalence is more likely than non-equivalence); category III (non-equivalence is
more likely than equivalence); and category IV (indicating non-equivalence).
11 Early population, ﬁnal population, time to silking, time to pollen shed, plant height, ear height, yield, pollen colour (measured
at 0, 30, 60 and 120 minutes), pollen shape (measured at 0, 30, 60 and 120 minutes), stay green, herbicide injury (after each
of the four herbicide applications), disease incidence, insect damage, days to maturity, root lodging, stalk lodging and seedling
vigour.
12 Days to maturity, root lodging, stalk lodging, seedling vigour, pollen colour and shape (at 0 and 120 min) and herbicide injury
(at 4 time points).
13 Estimated mean values for plant height (cm) were 274.9 (non-GM comparator) and 284.6 (untreated GM maize); the
equivalence interval was (256.9–282.5). Estimated mean values for insect damage (% plant tissue/leaf area damaged) were
14.25 (non-GM comparator), 11.44 (untreated GM maize) and 13.95 (non-GM commercial reference varieties).
14 Estimated mean values for insect damage (% plant tissue/leaf area damaged) were as follows 14.25 (non-GM comparator),
11.78 (treated GM maize) and 13.95 (non-GM commercial reference varieties). Estimated mean values for pollen shape at
30 min were 58.88% (non-GM comparator), 63.5% (treated GM maize) and 59.76% (non-GM commercial reference varieties).
15 Sodium, furfural, ascorbic acid and the fatty acids caprylic (8:0), capric (10:0), lauric (12:0), myristic (14:0), myristoleic
(14:1), pentadecanoic (15:0), pentadecenoic (15:1), palmitoleic (16:1), heptadecanoic (17:0), heptadecenoic (17:1), c-
linolenic (18:3), eicosadienoic (20:2), eicosatrienoic (20:3) and arachidonic (20:4).
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limit of quantiﬁcation. The statistical analysis was applied to the remaining 65 constituents (9 in
forage16 and 56 in grain17). A summary of the outcome of the test of difference and the test of
equivalence is presented in Table 6:
• For the four-event stack maize not treated with the intended herbicides, 23 grain endpoints
showed statistically signiﬁcant differences with the non-GM comparator. All these endpoints fell
under equivalence category I or II, except for levels of isoleucine, rafﬁnose, manganese and b-
carotene which fell under equivalence category III or IV. Levels of cystine, phenylalanine, iron,
pyridoxine and folic acid in grain fell under equivalence category III or IV, although no
statistically signiﬁcant differences were identiﬁed with the non-GM comparator.
• For the four-event stack maize treated with the intended herbicides, 27 grain endpoints and
three forage endpoints showed statistically signiﬁcant differences with the non-GM comparator.
All these endpoints fell under equivalence category I or II, except for levels of cystine,
isoleucine, phenylalanine, rafﬁnose, manganese and b-carotene in grain, which fell under
equivalence category III or IV; and for total fat in forage, for which the test of equivalence
was not applied (because the variability associated to the non-GM reference varieties was
estimated to be zero). Levels of iron, pyridoxine and folic acid in grain fell under equivalence
category III or IV, although no statistically signiﬁcant differences were identiﬁed with the non-
GM comparator.
Table 6: Outcome of the comparative compositional analysis in grains and forage of maize
MON 89034 9 1507 9 NK603 9 DAS-40278-9. The table shows the number of endpoints
in each category
Test of difference(a)
Not-Treated(c) Treated(c)
Not
different
Signiﬁcantly
different
Not
different
Signiﬁcantly
different
Test of
equivalence(b)
Category I/II 36 19(d) 32 23(d)
Category III/IV 5(e) 4(f) 3(e) 6(f)
Not categorised 1(g) – – 1(g)
Total endpoints 65 65
(a): Comparison between maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 and its non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not-treated with the intended herbicides (see Section 3.3.2.1).
(d): Endpoints with signiﬁcant differences between maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 and its non-GM
comparator falling in equivalence category I-II (treated and not treated).
For grain, both treated and not treated: glutamic acid, glycine, leucine, threonine, tryptophan, 18:1 oleic, 18:2 linoleic, 20:1
eicosenoic, protein, copper and zinc. For not treated only: aspartic acid, ferulic acid, phytic acid, 20:0 arachidic, ash,
moisture, magnesium and riboﬂavin (B2). For treated only: arginine, histidine, inositol, 18:3 linolenic, ADF, carbohydrates,
total fat, calcium, phosphorus and niacin (B3).
For forage: calcium and phosphorus (treated only).
(e): The following endpoints in grain fell under equivalence category III or IV, although no statistically signiﬁcant differences
were identiﬁed with respect to the conventional counterpart: iron, pyridoxine (B6) and folic acid (B9) (both treated and not
treated), cystine and phenylalanine (non-treated only).
(f): Endpoints with signiﬁcant differences between maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 and its non-GM
comparator and falling in equivalence category III-IV. Quantitative results for these endpoints are reported in Table 7.
(g): The endpoint total fat in forage was not categorised for equivalence. Quantitative results are reported in Table 7.
16 Protein, fat, ash, moisture, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), calcium and phosphorus.
17 Proximates (protein, fat ash, moisture and carbohydrates by calculation), ﬁbre fractions (acid detergent ﬁbre (ADF), neutral
detergent ﬁbre (NDF) and total detergent ﬁbre (TDF)), minerals (calcium, copper, iron, magnesium, manganese, phosphorus,
potassium, selenium and zinc), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine,
isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine), fatty acids
(palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), arachidic acid (20:0),
eicosenoic acid (20:1) and behenic acid (22:0)), vitamins (b-carotene, thiamine, riboﬂavin, niacin, pyridoxine, folic acid and a-
tocopherol) and other compounds (inositol, p-coumaric acid, ferulic acid, phytic acid, rafﬁnose and trypsin inhibitor).
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The GMO Panel assessed all signiﬁcant differences between the four-event stack maize and the
non-GM comparator, taking into account potential impact on plant metabolism and the natural
variability observed for the set of non-GM commercial reference varieties. Quantitative results for the
endpoints showing signiﬁcant differences between the four-event stack maize and the non-GM
comparator and not falling under category I/II are given in Table 7.
3.3.2.4. Conclusion on comparative analysis
The GMO Panel concludes that the differences in the agronomic and phenotypic characteristics
identiﬁed between the four-event stack maize and its non-GM comparator do not require further
assessment, except for plant height, insect damage and pollen shape at 30 min. These differences are
further assessed for their environmental impact in Section 3.3.4.1.
The GMO Panel concludes that none of the differences identiﬁed in forage and grain composition
between the four-event stack maize, its non-GM comparator and the non-GM commercial reference
varieties needs further assessment regarding food and feed safety, except for the changes in levels of
cystine, isoleucine, phenylalanine, rafﬁnose, manganese and b-carotene in grain and in levels of total
fat in forage, which are further assessed in Section 3.3.3.
3.3.3. Food and feed safety assessment18
3.3.3.1. Effects of processing
The four-event stack maize will undergo existing production processes used for conventional maize.
Based on the outcome of the comparative assessment, processing of the four-event stack maize into
food and feed products is not expected to result in products being different from those of non-GM
maize varieties.
Table 7: Quantitative results (estimated means and equivalence limits) for compositional endpoints
in grain and forage that are further assessed based on the results of the statistical analysis
Endpoint
Maize
MON 89034 3 1507 3 NK603
3 DAS–40278–9
Non-GM
comparator
Non-GM reference varieties
Not treated Treated(a) Mean Equivalence limits
Forage
Total fat
(% dw)
2.024 1.966* 2.172 2.001 –
Grain
Cystine
(% AA)
1.902 1.866* 1.927(b) 2.085 (1.928, 2.254)
Isoleucine
(% AA)
3.780* 3.784* 3.746 3.685 (3.600, 3.769)
Phenylalanine
(% AA)
5.305 5.352* 5.276(b) 5.087 (4.925, 5.257)
Rafﬁnose
(% dw)
0.115* 0.108* 0.102(b) 0.200 (0.121, 0.330)
Manganese
(mg/100 g dw)
0.489* 0.496* 0.518 0.596 (0.503, 0.690)
b-Carotene
(mg/kg dw)
3.612* 3.476* 3.360(b) 1.260 (0.735, 1.787)
dw: dry weight; % AA: percentage total amino acid.
For the GM maize, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by the greyscale background: white (the test of equivalence was not performed), light grey (equivalence
category III) and dark grey (equivalence category IV).
(a): Treated with the intended herbicides as described in Section 3.3.2.1.
(b): Mean values for cystine, phenylalanine, rafﬁnose and b-carotene in the non-GM comparator were out of the equivalence
limits derived from the selected non-GM reference varieties.
18 Dossier: Part II – Sections A.4, A.5 and A.6; Additional information: 19/9/2017 and 30/7/2018.
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3.3.3.2. Inﬂuence of temperature and pH on newly expressed proteins
Effects of temperature and pH on Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4 EPSPS and AAD-1 proteins
have been previously evaluated by the GMO Panel (Table 2). In the context of this application, no new
studies addressing these aspects were provided by the applicant.
3.3.3.3. Toxicology
Testing of newly expressed proteins
Six proteins (Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4 EPSPS19 and AAD-1) are newly expressed in the
four-event stack maize (see Section 3.1). The GMO Panel has previously assessed these proteins in the
context of the single maize events (see Table 2), and no safety concerns were identiﬁed for humans
and animals. The GMO Panel is not aware of any new information that would change these
conclusions.
The potential for a functional interaction between the proteins newly expressed in the four-event
stack maize has been assessed with regard to human and animal health. The CP4 EPSPS, PAT and
AAD-1 proteins are enzymes that catalyse distinct biochemical reactions and act on unrelated
substrates with high substrate speciﬁcity. The Cry1A.105, Cry2Ab2 and Cry1F proteins are delta
endotoxins with high speciﬁc insecticidal properties acting through cellular receptors found in target
insect species. It is reported that the gastrointestinal tract of mammals, including humans, lacks
receptors with high speciﬁc afﬁnity to Cry proteins (Hammond et al., 2013; Koch et al., 2015). On the
basis of the known biological functions of the individual newly expressed proteins (see Table 4), there
is currently no expectation for possible interactions relevant for the food and feed safety of the four-
event stack maize.
In vitro protein degradation studies on Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4 EPSPS and AAD–1
proteins have been previously evaluated by the GMO Panel (see Table 2). In the context of this
application, no new studies addressing in vitro protein degradation of these newly expressed proteins
were provided by the applicant.
The GMO Panel concludes that there are no safety concerns for human and animal health related
to the newly expressed proteins Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4 EPSPS and AAD-1 in the four-
event stack maize.
Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identiﬁed in the four-event
stack maize. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
Information on altered levels of food and feed constituents
Cystine, isoleucine, phenylalanine, rafﬁnose, manganese and b-carotene in grain and total fat in
forage were signiﬁcantly different in the four-event stack maize when compared to its comparator and
showed lack of equivalence with the set of non-GM reference varieties (see Section 3.3.2.3). Taking
into account the known biological role of these compounds, these differences are considered of no
toxicological concern by the GMO Panel. Further information on the safety of these maize constituents
is provided in Section 3.3.3.5.
Testing of the whole genetically modiﬁed food and feed
Based on the outcome of the studies considered in the molecular characterisation and comparative
analysis, no substantial modiﬁcations of toxicological relevance in the composition of the four-event
stack maize, and no indication of possible unintended effects relevant to food and feed safety have
been identiﬁed (see Sections 3.3.1. and 3.3.2.3). Therefore, animal studies on food and feed from the
four-event stack maize are not necessary (EFSA GMO Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufﬁcient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed protein or
19 Including its variant CP4 EPSPS L214P.
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structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed protein
For allergenicity, the GMO Panel has previously evaluated the safety of Cry1A.105, Cry2Ab2, Cry1F,
PAT, CP4 EPSPS and AAD-1 proteins individually, and no concerns on allergenicity were identiﬁed in the
context of the applications assessed (see Table 2). No new information on allergenicity of these
proteins that might change the previous conclusions of the GMO Panel has become available. Based on
the current knowledge, and as none of the newly expressed proteins showed allergenicity, no reasons
for concerns regarding the simultaneous presence of these newly expressed proteins in the four-event
stack maize affecting their allergenicity are expected.
For adjuvanticity, Cry1Ac protein has been suggested to possess adjuvant activity based on animal
studies when applied at relatively high doses (e.g. Vazquez et al., 1999). The Panel has previously
evaluated the safety of Cry1A.105, Cry2Ab2 and Cry1F proteins, and no concerns on adjuvanticity
were identiﬁed in the context of the applications assessed (see Table 2). The levels of the individual
Cry proteins in the four-event stack maize are similar to those of the three-event stack
MON 89034 9 1507 9 NK603 (see Appendix 1). From the limited evidence available, the GMO
Panel does not ﬁnd indications that the presence of the Cry proteins at the levels expressed in the
four-event stack maize might act as adjuvants with the potential to enhance a speciﬁc immunoglobulin
E (IgE) response and to favour the development of an allergic reaction.
Assessment of allergenicity of the whole GM plant
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered to be a common allergenic food20 (OECD, 2002). Therefore, the
GMO Panel does not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application, and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1, 3.3.2
and 3.3.3), the GMO Panel identiﬁes no indications of a potentially increased allergenicity of foods and
feeds from the four-event stack maize with respect to those from its non-GM comparator.
3.3.3.5. Nutritional assessment of GM food and feed
The intended trait of the four-event stack maize is insect resistance and herbicide tolerance, with
no intention to alter the nutritional parameters. However, levels of cystine, isoleucine, phenylalanine,
rafﬁnose, manganese and b-carotene in grain were signiﬁcantly different from its non-GM comparator
and showed a lack of equivalence with the set of non-GM reference varieties (see Section 3.3.2.3). In
addition, for total fat in forage from the GM-maize the levels were signiﬁcantly different from its non-
GM comparator and the test of equivalence could not be applied because of the lack of variation
among the non-GM reference varieties. The biological role of these compounds, the contribution of
maize to their total intake and the magnitude and direction of the observed changes are considered in
the nutritional assessment.
Human nutrition
Among the three amino acids showing signiﬁcant differences as compared to the non-GM
comparator, two of them are essential amino acids: isoleucine and phenylalanine. For these two amino
acids an increase of approximately 1% (percentage of total amino acids) is observed in the GM maize
as compared to the non-GM comparator. For cystine, the oxidised dimer form of the non-essential
amino acid cysteine, a decrease of approximately 3% was observed as compared to the non-GM
comparator. Overall, these changes are not considered relevant from a nutritional point of view.
Rafﬁnose is a non-digestible trisaccharide composed of galactose, fructose and glucose, considered
as an antinutrient since cannot be broken down by gastrointestinal enzymes; as a consequence,
20 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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rafﬁnose passes into the large intestine where is fermented by the intestinal microﬂora causing
ﬂatulence (OECD, 2002). An increase of approximately 13% in the levels of rafﬁnose in the GM-maize
is observed as compared to the non-GM comparator. Maize contains very small amounts of rafﬁnose as
compared to other foods of plant origin such as soybean, garlic and onions among many others. Based
on this, and considering that a daily dose of 15 g of rafﬁnose is considered safe (Voragen, 1998), the
increase observed in rafﬁnose is not considered relevant from a nutritional point of view.
b-Carotene is a precursor of vitamin A and is found in plant derived foods; together with preformed
vitamin A (mainly retinol and retinyl esters) present in foods of animal origin, it contributes to the total
dietary intake of vitamin A. Milk, meat, vegetables and derived products are the main sources of
vitamin A in the diet (EFSA NDA Panel, 2012). An increase up to approximately 8% is observed as
compared to the non-GM comparator (from 560 lg RE21/kg dw to 602 lg RE/kg dw). Considering the
magnitude of the change, the consumption of maize and the Tolerable Upper Intake Levels (UL) for
vitamin A (800–3,000 lg RE/day), the increase observed in b-carotene is not considered relevant from
a nutritional point of view.
Manganese is an essential dietary mineral which is a component of a number of metalloenzymes
involved in amino acid, lipid and carbohydrate metabolism. Nuts, dried fruits and chocolate are the
main dietary sources of manganese; cereal-based products also contribute to its intake mainly due to
the levels found in wheat grain (25 mg/kg, Bawiec et al., 2014). A decrease of up to approximately
6% is observed in the GM maize as compared to the non-GM comparator. Considering the relatively
low levels in maize, the magnitude of the change and the relatively low contribution of maize to the
dietary intake of manganese, the observed decrease is not considered relevant from a nutritional point
of view.
Animal nutrition
Cystine is a conditionally essential amino acid. The magnitude of the decrease observed in the GM
maize as compared to the non-GM comparator does not constitute an issue for animal nutrition.
Isoleucine and phenylalanine are essential amino acids and the increase observed in the GM-maize as
compared to the non-GM comparator is not an issue for animal nutrition.
Rafﬁnose is fermented in the forestomachs (ruminants) and in the hind gut (rabbit, horse) and
provides energy. High level of rafﬁnose in monogastric diet is detrimental to digestion and production
performance, but maize contains very low level of rafﬁnose as compared to other common feed used
in animal diets, such as soybean. Rafﬁnose, in speciﬁc conditions, has been demonstrated to be a
prebiotic compound that can improve intestinal health in poultry and ﬁshes. Taking into account the
magnitude and the biological role of these changes, these do not to pose an issue for animal nutrition.
Manganese is an important trace element in animal nutrition; the decreased level observed does
not constitute an issue, since complete diets are balanced with mineral premixes. Moreover, maize
grains are also considered a poor source of manganese (McDonald et al., 2011).
b-Carotene is converted in the liver into retinol and an increase does not represent an issue for
animal health.
Forage is not provided to animals as source of fat; a decrease in total fat content of forage does
not affect animal nutrition since complete diets are balanced to energy content.
Conclusion on human and animal nutrition
Based on the current knowledge on the biological role of the compounds assessed, the magnitude
and direction of the changes identiﬁed, and the relevance of maize as contributor to the intake of
these compounds, the GMO Panel concludes that the nutritional impact of foods and feeds from the
four-event stack maize is expected to be the same as those from the comparator and non-GM
reference varieties.
3.3.3.6. Conclusion on food and feed safety assessment
The individual proteins Cry1A.105, Cry2Ab2, Cry1F, PAT, CP4 EPSPS and AAD-1 newly expressed in
the four-event stack maize do not raise safety concerns for human and animal health. Interactions
between these newly expressed proteins raising food and feed safety concerns (toxicological,
allergenicity and adjuvanticity) are not expected. The nutritional impact of the four-event stack maize
foods and feeds is expected to be the same as those from the comparator and non-GM reference
21 RE: retinol equivalent. One lg RE equals 6 µg of b-carotene.
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varieties. The GMO Panel concludes that the four-event stack maize, as described in this application, is
as safe as and nutritionally equivalent to the comparator and the non-GM reference varieties tested.
3.3.4. Environmental risk assessment22
Considering the scope of application EFSA-GMO-NL-2013-112, which excludes cultivation, the
environmental risk assessment (ERA) of the four-event stack maize mainly takes into account: (1) the
exposure of microorganisms to recombinant DNA in the gastrointestinal tract of animals fed GM
material and of microorganisms present in environments exposed to faecal material of these animals
(manure and faeces); and (2) the accidental release into the environment of viable four-event stack
maize grains during transportation and/or processing (EFSA GMO Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may occur
outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a combination of
low competitiveness, the absence of a dormancy phase and susceptibility to plant pathogens, herbivores
and cold climate conditions (OECD, 2003). Field observations indicate that maize grains may survive and
overwinter in some EU regions, resulting in volunteers in subsequent crops (e.g. Gruber et al., 2008;
Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers have been shown to grow weakly
and ﬂower asynchronously with the maize crop (Palaudelmas et al., 2009). Thus, the establishment and
survival of feral and volunteer maize in the EU is currently limited and transient.
It is unlikely that the intended traits of the four-event stack maize and the observed differences in
plant height, insect damage and pollen shape at 30 min (see Section 3.3.2.2) will provide a selective
advantage to maize plants, except when they are exposed to glufosinate-ammonium-, glyphosate-,
2,4-D and/or AOPP-containing herbicides, or infested by insect pests that are susceptible to the
Cry1A.105, Cry2Ab2 and/or Cry1F proteins. However, this ﬁtness advantage will not allow the four-
event stack maize to overcome other biological and abiotic factors (described above) limiting plant’s
persistence and invasiveness. Therefore, the presence of the intended traits and the observed
differences in plant height, insect damage and pollen shape at 30 min do not affect the persistence
and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that the four-event stack maize will differ
from conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable four-event stack maize grains.
3.3.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene ﬂow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel scientiﬁc opinions for the single events (see Table 2). No concern as a result of
an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut of
domesticated animals and humans fed GM material or other receiving environments was identiﬁed.
The applicant submitted an updated bioinformatic analysis for each of the single events in order to
assess the possibility for HGT by homologous recombination.
The updated bioinformatic analysis for maize event 1507 revealed sufﬁcient length and sequence
identity for homologous recombination for two copies of the ORF25 terminator with the same
A. tumefaciens genomic sequence. Because of its length (~700 bp) and the opposite orientation of the
two ORF25 copies in maize event 1507, a potential for a facilitated HGT by double homologous
recombination (DHR) is unlikely. The occurrence of a DHR would result in the insertion of the pat gene
cassette which is expected to be less efﬁciently translated in potential bacterial recipients because of
the plant-codon optimisation of the pat gene and because the pat gene is under the control of plant
virus element.
22 Dossier: Part II – Section E; Additional information: 30/7/2018.
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The updated bioinformatic analysis for maize events MON 89034 and NK603 do not reveal any new
DNA sequence that could provide sufﬁcient length and identity which could facilitate HGT by DHR,
conﬁrming the previous conclusions (EFSA GMO Panel, 2017b,c,d).
Bioinformatic analysis for maize event DAS-40278-9 does not reveal sufﬁcient length and sequence
identity with known sequences from bacteria which would facilitate homologous recombination.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for horizontal gene transfer or a selective
advantage are not identiﬁed.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this four-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to-plant gene transfer
The potential for occasional feral four-event stack maize plants originating from grain import spills
to transfer recombinant DNA to sexually compatible plants and the environmental consequences of this
transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003;
EFSA, 2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016, Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.3.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe would not differ from that of conventional maize varieties for the reasons given
in Section 3.3.4.1, even if exposed to the intended herbicides.
3.3.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2013-112 into account (no cultivation), potential
interactions of occasional feral four-event stack maize plants arising from grain import spills with target
organisms are not considered a relevant issue.
3.3.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled four-event stack maize grains is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
maize, potential interactions of the four-event stack maize with non-target organisms are not
considered to raise any environmental safety concern. Interactions that may occur between the Cry
proteins would not alter this conclusion.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral four-event stack maize
plants arising from grain import spills is limited, and because ingested proteins are degraded before
entering the environment through faecal material of animals fed GM maize, potential interactions with
the abiotic environment and biogeochemical cycles are not considered to raise any environmental
safety concern.
3.3.4.6. Conclusions on environmental risk assessment
The GMO Panel concludes that it is unlikely that the four-event stack maize would differ from
conventional maize varieties in its ability to persist under EU environmental conditions. Considering the
scope of application EFSA-GMO-NL-2013-112, interactions of occasional feral four-event stack maize
plants with the biotic and abiotic environment are not considered to be relevant issues. The analysis of
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HGT from the four-event stack maize to bacteria does not indicate a safety concern. Therefore,
considering the combined traits and their interactions, the outcome of the comparative analysis, and
the routes and levels of exposure, the GMO Panel concludes that the four-event stack maize would not
raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
3.3.5. Conclusion on the four-event stack maize MON 89034 3 1507 3 NK603 3
DAS–40278–9
No new data on the single maize events MON 89034, 1507, NK603 and DAS-40278-9 leading to a
modiﬁcation of the original conclusions on their safety are identiﬁed.
The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicates
that the combination of the single maize events and of the newly expressed proteins in the four-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the four-event stack, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested.
Considering the combined traits and their interactions, the outcome of the comparative analysis,
and the routes and levels of exposure, the GMO Panel concludes that the four-event stack maize
would not raise safety concerns in the case of accidental release of viable GM maize grains into the
environment.
No scientiﬁc information that could change the conclusions on this four-event stack was retrieved in
a literature search covering the period since the time of validity of the application.23
In conclusion, the GMO Panel considers that the four-event stack maize is as safe as its non-GM
comparator and the non-GM maize reference varieties tested with respect to potential effects on
human and animal health and the environment.
3.4. Risk assessment of the subcombinations24
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.4.1.
The strategy followed for the assessment of those subcombinations for which no speciﬁc data have
been submitted and which have not been previously assessed by the GMO Panel (see Table 8), has
been described by the GMO Panel.25 In this case, the risk assessment takes as its starting point the
assessment of the single maize events, and uses the data generated for the four-event stack, as well
as all the additional data available on subcombinations previously assessed by the GMO Panel (see
Table 2).
3.4.1. Subcombinations previously assessed
The GMO Panel has previously assessed the two-event maize stacks MON 89034 9 1507,
MON 89034 9 NK603 and 1507 9 NK603, and the three-event maize stack MON 89034 9 1507 9 NK603
(see Table 2) and did not identify any safety concerns. No scientiﬁc information relevant to the risk
assessment of these maize stacks became available since the validation of application EFSA-GMO-NL-
2013-112. Consequently, the GMO Panel considers that its previous conclusions on these
subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
Six out of the ten subcombinations included in the scope of this application have not been
previously assessed by the GMO Panel, and no experimental data were provided for these maize stacks
(see Table 8).
23 Additional information: 22/12/2017.
24 Additional information: 7/5/2018 and 27/7/2018.
25 115th GMO Panel meeting (Annex 1 of the minutes: https://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf)
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3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the four single maize events
has been demonstrated previously (see Table 2). Integrity of the events has been demonstrated in the
four-event stack maize (Section 3.3.1.2) and the previously assessed maize subcombinations
(see Table 2). The GMO Panel ﬁnds no reasons to expect loss of integrity of the events in the maize
subcombinations not previously assessed (see Table 8).
3.4.2.2. Expression of the events
The GMO Panel assessed whether any combination of the four events by conventional crossing could
result in signiﬁcant changes in expression levels of the newly expressed proteins, as this could indicate
an unexpected interaction between the events. Based on current knowledge of the molecular elements
introduced, there is no reason to expect interactions that would affect the levels of the newly expressed
proteins in the subcombinations compared with those in the single maize events. This assumption is
conﬁrmed by comparing the levels of the newly expressed AAD-1 protein of the single event maize
DAS-40278-9 and CP4 EPSPS, Cry1A.105, Cry2Ab2, Cry1F and PAT proteins of the three-event maize
stack maize MON 89034 9 1507 9 NK603 with those of the four-event stack maize. The levels were
similar in the four-event stack maize and in maize DAS-40278-9 and MON 89034 9 1507 9 NK603.
Therefore, there is no indication of an interaction manifesting at protein expression level. This conﬁrms
that interactions affecting expression levels of the newly expressed proteins are not expected in the six
maize subcombinations not previously assessed and included in the scope of application EFSA-GMO-NL-
2013-113.
3.4.2.3. Potential functional interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the
subcombinations not previously assessed (Table 8), taking into consideration the intended traits and
unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions relevant for the food and feed or environmental
safety between these proteins in the six subcombinations not previously assessed. The GMO
Panel took into account all the intended and potential unintended effects considered in the assessment
of the four single events, the previously assessed subcombinations (Table 2) and the four-event stack
maize. It is concluded that none of these effects would raise safety concerns when combined in any of
these maize subcombinations. Therefore, the GMO Panel is of the opinion that no additional data are
needed to complete the assessment of subcombinations from the four-event stack maize.
3.4.3. Conclusion
Since no new safety concerns are identiﬁed for the previously assessed two-event stack maize
MON 89034 9 1507, MON 89034 9 NK603 and 1507 9 NK603 as well as for the three-event stack
maize MON 89034 9 1507 9 NK603, the GMO Panel considers that its previous conclusions on these
maize subcombinations remain valid. For the remaining six subcombinations included in the scope of
application EFSA-GMO-NL-2013-112 for which no experimental data have been provided, the GMO
Panel has assessed the possibility of interactions between the events and concludes that these
combinations would not raise safety concerns. These subcombinations are therefore expected to be as
safe as and nutritionally equivalent to the single maize events, the previously assessed two-event
Table 8: Subcombinations of maize MON 89034 9 1507 9 NK603 9 DAS-40278-9 not previously
assessed and covered by the scope of application EFSA-GMO-NL-2013-112
Degree of stacking Events
Three-event stack maize MON 89034 9 NK603 9 DAS-40278-9
MON 89034 9 1507 9 DAS-40278-9(a)
1507 9 NK603 9 DAS-40278-9
Two-event stack maize MON 89034 9 DAS-40278-9(a)
1507 9 DAS-40278-9(a)
NK603 9 DAS-40278-9
(a): Subcombinations assessed in parallel in the context of application EFSA-GMO-NL-2013-113 (EFSA GMO Panel, 2019).
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maize stacks MON 89034 9 1507, MON 89034 9 NK603 and 1507 9 NK603 and the three-event stack
maize MON 89034 9 1507 9 NK603 as well as the four-event stack maize.
3.5. Post-market monitoring26
3.5.1. Post-market monitoring of GM food and feed
The GMO Panel concludes that four-event stack maize, as described in this application, is
nutritionally equivalent to and as safe as the non-GM comparator and the non-GM reference varieties
tested, and no post-market monitoring (EFSA GMO Panel, 2011a) of food and feed is considered
necessary.
The two-event stack maize MON 89034 9 1507, MON 89034 9 NK603 and 1507 9 NK603 and the
three-event stack maize MON 89034 9 1507 9 NK603 have been previously assessed and no safety
concerns were identiﬁed. The six subcombinations not previously assessed and included in the scope
of application EFSA-GMO-NL-2013-112 are expected to be as safe as and nutritionally equivalent to the
single maize events, the previously assessed maize subcombinations and the four-event stack maize
MON 89034 9 NK603 and 1507 9 NK603. Therefore, the GMO Panel considers that post-market
monitoring of the four-event stack maize and its subcombinations, as described in this application, is
not necessary.
3.5.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are: (1) to conﬁrm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) to identify the
occurrence of adverse effects of the GMO, or its use, on human health or the environment that were
not anticipated in the ERA.
Monitoring is related to risk management, and thus, a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA does not identify potential adverse environmental effects from the four-event stack
maize, no case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for the four-event stack maize and its subcombinations
includes: (1) the description of a monitoring approach involving operators (federations involved in
import and processing), reporting to the applicant, via a centralised system, any observed adverse
effect(s) of GMOs on human health and the environment; (2) a coordinating system established by
EuropaBio for the collection of information recorded by the various operators; and (3) the review of
relevant scientiﬁc publications retrieved from literature searches (Lecoq et al., 2007; Windels et al.,
2008). The applicant proposes to submit a PMEM report on an annual basis and a ﬁnal report at the
end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the four-event stack maize. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. The PMEM plan and reporting intervals are in line
with the intended uses of the four-event stack maize and its subcombinations.
3.5.3. Conclusion on post-market monitoring
No post market monitoring for food and feed is necessary. The scope of the PMEM plan provided
by the applicant and the reporting intervals are in line with the intended uses of the four-event stack
maize and its subcombinations.
4. Overall conclusions and recommendations
No new data on the four single maize events MON 89034, 1507, NK603 and DAS-40278-9 that
would lead to a modiﬁcation of the original conclusions on their safety are identiﬁed.
The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics), and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the four-event
26 Dossier: Part II – Sections D and E4.
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stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the four-event stack maize, as described in this application, is as safe as
and nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested, and
no post-market monitoring of food and feed is considered necessary.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from the four-event stack maize into the environment.
Since no new data on the previously assessed two-event stack maize MON 89034 9 1507,
MON 89034 9 NK603 and 1507 9 NK603 and the three-event stack maize MON 89034 9 1507 9 NK603
that would lead to a modiﬁcation of the original conclusions on their safety are identiﬁed, the GMO
Panel considers that its previous conclusions on these maize stacks remain valid.
For the additional six maize subcombinations included in the scope of application EFSA-GMO-NL-
2013-112 for which no experimental data have been provided, the GMO Panel assessed possible
interactions between the events, and concludes that combinations of maize events MON 89034, 1507,
NK603 and DAS-40278-9 would not raise safety concerns in these maize subcombinations. These
subcombinations are therefore expected to be as safe as and nutritionally equivalent to the single
maize events, all the previously assessed subcombinations and the four-event stack maize.
Given the absence of safety concerns for foods and feeds from the four-event stack maize and all
its subcombinations, the GMO Panel considers that post-market monitoring of these products is not
necessary.
The PMEM plan provided by the applicant and the reporting intervals are in line with the intended
uses of the four-event stack maize and its subcombinations.
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Abbreviations
2,4-D 2,4-dichlorophenoxyacetic acid
AAD-1 aryloxyalkanoate dioxygenase 1
ADF acid detergent ﬁbre
AOPP aryloxyphenoxypropionate
cry crystal protein
DHR double homologous recombination
Dw dry weight
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
GM genetically modiﬁed
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
HGT horizontal gene transfer
IgE immunoglobulin E
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PAT phosphinothricin acetyltransferase
PPP plant protection products
PMEM post-market environmental monitoring
RE retinol equivalent
TDF total detergent ﬁbre
UL tolerable upper intake levels
UTR untranslated region
WSR Wilcoxon signed-rank
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Appendix A – Protein expression data
Mean, standard deviation and range of protein levels (lg/g dry weight) from maize MON 89034 9
1507 9 NK603 9 DAS-40278-9, MON 89034 9 1507 9 NK603, and DAS-402789 unsprayed tissues
from ﬁeld trials performed across 10 locations in the US in 2010 (n = 40)
DAS-40278-9
MON 89034 3
1507 3 NK603
MON 89034 3 1507 3
NK603 3 DAS-40278-9
AAD-1
Leaf (V2-V4) 11.81  6.28
(2.59–24.32)
11.83  6.13
(2.40–24.39)
Leaf (V9) 4.43  2.53
(0.41–12.07)
4.23  1.48
(0.65–7.44)
Pollen (R1) 97.28  14.23
(61.52–132.26)
100.95  12.97
(78.60–131.70)
Root (R1) 4.16  2.33
(0.71–11.24)
3.90  1.86
(0.92–10.22)
Leaf (R1) 6.05  2.41
(2.10–11.32)
6.40  2.95
(1.73–14.22)
Forage (R4) 4.79  1.41
(ND–8.26)
4.43  1.39
(1.83–7.46)
Whole plant (R6) 4.95  2.28
(ND–11.61)
5.37  2.57
(1.52–12.47)
Grain R6 3.04  1.02
(1.27–6.71)
3.03  0.74
(1.37–5.47)
CP4-EPSPS
Leaf (V2–V4) 158.50  40.11
(94.00–252.99)
162.19  43.39
(103.00–279.04)
Leaf (V9) 107.37  15.23
(67.00–139.75)
108.66  25.44
(64.00–191.95)
Pollen (R1) 192.88  42.25
(124.00–287.37)
186.91  41.96
(86.35–265.53)
Root (R1) 42.21  8.85
(21.73–66.59)
40.26  10.29
(13.07–94.18)
Leaf (R1) 86.88  16.65
(47.50–134.89)
97.54  15.25
(60.00–138.90)
Forage (R4) 59.46  11.38
(22.23–97.08)
57.85  16.56
(23.05–106.00)
Whole plant (R6) 30.69  16.24
(11.41–73.34)
32.83  15.72
(7.23–67.87)
Grain (R6) 7.57  2.34
(3.89–13.32)
7.94  1.97
(3.44–15.28)
Cry1A.105
Leaf (V2–V4) 148.44  39.15
(76.57–223.79)
155.51  57.17
(67.60–281.33)
Leaf (V9) 51.73  29.14
(19.99–130.71)
53.48  24.39
(16.86–147.51)
Pollen (R1) 15.50  2.24
(ND–19.10)
15.15  1.61
(12.25–18.15)
Root (R1) 22.27  7.50
(10.30–39.84)
21.05  9.54
(7.56–42.72)
Leaf (R1) 30.60  16.57
(7.02–80.80)
32.95  16.23
(10.04–84.70)
Forage (R4) 27.04  5.84
(16.19–41.63)
26.71  5.54
(16.06–41.27)
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DAS-40278-9
MON 89034 3
1507 3 NK603
MON 89034 3 1507 3
NK603 3 DAS-40278-9
Whole plant (R6) 10.55  5.57
(4.09–32.95)
9.94  3.96
(4.33–26.35)
Grain (R6) 4.81  1.08
(2.28–10.00)
4.91  0.64
(3.09–6.96)
Cry2Ab2
Leaf (V2–V4) 142.80  59.34
(52.20–273.00)
146.21  59.52
(66.90–281.70)
Leaf (V9) 60.23  18.70
(25.80–106.23)
64.00  20.83
(30.00–118.09)
Pollen (R1) 1.30  0.61
(0.50–2.88)
1.27  0.58
(0.43–2.91)
Root (R1) 31.99  9.79
(14.10–49.74)
28.29  7.89
(ND–50.85)
Leaf (R1) 48.85  18.44
(14.10–88.74)
52.85  15.31
(23.10–83.85)
Forage (R4) 51.25  10.44
(15.75–72.45)
49.53  11.79
(27.60–82.50)
Whole plant (R6) 34.04  24.58
(8.83–99.46)
31.96  17.82
(10.93–88.61)
Grain (R6) 3.35  0.78
(2.17–6.00)
3.34  0.89
(1.38–6.25)
Cry1F
Leaf (V2–V4) 14.81  3.59
(8.45–24.55)
16.29  4.54
(9.50–27.26)
Leaf (V9) 9.06  3.69
(2.48–18.81)
8.82  3.94
(1.57–21.32)
Pollen (R1) 19.15  3.43
(13.02–25.74)
18.86  4.21
(11.31–26.60)
Root (R1) 4.71  1.03
(2.42–6.96)
4.56  1.34
(2.22–7.58)
Leaf (R1) 7.12  3.77
(0.51–14.64)
7.61  3.28
(0.48–12.90)
Forage (R4) 8.23  1.89
(1.94–11.22)
7.99  2.18
(1.77–13.24)
Whole plant (R6) 4.26  1.15
(2.31–6.81)
4.59  1.39
(2.22–8.28)
Grain (R6) 2.21  0.58
(1.32–3.85)
2.50  0.44
(1.32–3.79)
PAT
Leaf (V2–V4) 8.11  5.66
(ND–23.28)
8.23  5.13
(2.40–20.92)
Leaf (V9) 6.29  6.91
(1.86–29.22)
5.00  2.99
(1.23–12.64)
Pollen (R1) ND  N/A
(ND–ND)
ND  N/A
(ND–ND)
Root (R1) 0.16  0.06
(0.06–0.35)
0.14  0.06
(ND–0.24)
Leaf (R1) 3.66  1.35
(1.81–7.12)
4.00  1.35
(1.21–7.12)
Forage (R4) 0.34  0.10
(0.13–0.60)
0.35  0.13
(0.06–0.75)
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DAS-40278-9
MON 89034 3
1507 3 NK603
MON 89034 3 1507 3
NK603 3 DAS-40278-9
Whole plant (R6) ND  N/A
(ND–0.06)
ND  N/A
(ND–0.09)
Grain (R6) ND  N/A
(ND–ND)
ND  N/A
(ND–ND)
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